Top Markets
#1 Black Phoenix Black Phoenix +197.98%
#2 Islamic Coin Islamic Coin +157.94%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +48.15%
#5 BasedHype BasedHype +39.22%
#6 Acurast Acurast +26.47%
#7 Cryptopia Cryptopia +21.79%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +20.90%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#10 Moolah Moolah +16.27%
Coin of the day
Black Phoenix Black Phoenix
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Imaging Biometrics Ltd. Imaging Biometrics Ltd.

Imaging Biometrics Ltd.

IBAI
Classificação em ações #41324
Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier,... Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier, Jersey, specializes in medical imaging diagnostics and clinical patient care. The company extends its services across the United Kingdom, Switzerland, the European Union, and the United States. Its operations are structured into three main segments: a Holding Company, Medical Software, and Oral Gallium Maltolate (GaM). The Medical Software division develops a comprehensive suite of ready-to-use software applications for the healthcare sector. This portfolio includes IB Clinic, which serves as the foundational platform for all IB software; IB Neuro, a specialized platform for MR DSC perfusion processing; and IB Delta Suite, designed to generate Delta T1 maps from routine MR examinations. Further offerings comprise IB DCE and IB Diffusion, both providing in-depth insights into blood flow and water diffusion throughout the body. For non-invasive assessments, the company provides StoneChecker and Liver Surface Nodularity, which are computed tomography (CT) processing tools that assist clinicians in evaluating kidney stones and liver health. Additional software includes IB ASL, used to measure cerebral blood flow for diagnosing conditions like stroke and dementia, and IB Zero G, an innovative technology that eliminates the need for gadolinium contrast agents in standard imaging. The suite also features IB Nimble, facilitating virtual collaboration among healthcare professionals. Beyond software, the company's Oral Gallium Maltolate (GaM) segment is actively pursuing the development of IB003, a gallium maltolate drug candidate currently in Phase 1 clinical trials for treating glioblastoma. Imaging Biometrics Ltd. also offers consulting services. The entity, which was previously known as IQ-AI Limited, is slated to adopt the name Imaging Biometrics Ltd. in May 2025.
Preço da ação
$0.01088561
Valor de mercado
$26.86K
Variação (1 dia)
14.29%
Variação (1 ano)
33.61%
País
JE
Negociar Imaging Biometrics Ltd. (IBAI)

Categoria

Healthcare
Rácio P/E de Imaging Biometrics Ltd. (IBAI)
Rácio P/E em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Imaging Biometrics Ltd., o rácio P/E atual (TTM) é 0. No final de 2026, a empresa tinha um P/E de 0.
Histórico do rácio P/E da Imaging Biometrics Ltd. de 2026 a 2026
Rácio P/E no final de cada ano
Ano Índice P/E Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/E para empresas semelhantes ou concorrentes
Empresa Rácio P/E Diferença do rácio P/E País
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
 19.55 -
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
 72.09 -
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
 41.76 -
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
 -30.68 -
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
 - -
US
Como interpretar um P/E Ratio?

O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.

Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.

Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.